Dr Lal PathLabs Limited announced its un-audited financial results for the quarter and half-year ended September 30, 2026. Revenue saw a robust increase of 19.6% for Q2 FY27 and 19.4% for H1 FY27. EBITDA grew by 25.1% in Q2 FY27 and 26.7% in H1 FY27, with Profit After Tax (PAT) rising by 27.5% and 27.3% respectively for the same periods. The company also declared an interim dividend of 50%.
Dr Lal PathLabs Reports Strong Financial Performance for Q2 FY27
Dr Lal PathLabs Limited has announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company has demonstrated significant growth across key financial metrics, underscoring its strong market position in the diagnostic and healthcare services sector.
Key Financial Highlights
For the second quarter of Fiscal Year 2027 (Q2 FY27), Revenue increased by a notable 19.6% year-on-year, reaching Rs 874 Crore compared to Rs 731 Crore in the corresponding period of the previous year. For the half-year ended September 30, 2026 (H1 FY27), revenue grew by 19.4% to Rs 1,672 Crore from Rs 1,400 Crore.
EBITDA for Q2 FY27 surged by 25.1% to Rs 280 Crore, with a margin of 32.1%, up from Rs 224 Crore and a margin of 30.7% in Q2 FY26. For H1 FY27, EBITDA increased by 26.7% to Rs 528 Crore, maintaining a healthy margin of 31.6%.
Profit After Tax (PAT) for Q2 FY27 saw a significant rise of 27.5%, amounting to Rs 194 Crore compared to Rs 152 Crore in Q2 FY26. The margin for PAT stood at 22.2%. For H1 FY27, PAT grew by 27.3% to Rs 364 Crore, with a margin of 21.8%.
Dividend and Cash Position
The company’s board has declared an interim dividend of 50%, equivalent to Rs 5 per share. As of September 30, 2026, Dr Lal PathLabs maintained a strong liquidity position with Cash and Cash Equivalents totaling Rs 1,746 Crore.
Consolidated Financial Overview (in Rs Cr)
| Particulars | FY27 | FY26 | Gr% | FY27 | FY26 | Gr % |
|---|---|---|---|---|---|---|
| Q2 | ||||||
| Revenue | 874 | 731 | 19.6% | 1,672 | 1,400 | 19.4% |
| Material consumed | 162 | 142 | 314 | 271 | ||
| Employee benefit Expenses | 139 | 124 | 271 | 248 | ||
| Fees to collection centres | 129 | 109 | 245 | 204 | ||
| Other Expenses | 164 | 132 | 314 | 261 | ||
| Total Expenses | 594 | 507 | 17.2% | 1,144 | 984 | 16.3% |
| EBITDA | 280 | 224 | 25.1% | 528 | 416 | 26.7% |
| Margins | 32.1% | 30.7% | 31.6% | 29.7% | ||
| Other Income | 34 | 25 | 66 | 53 | ||
| Depreciation Cost | 47 | 41 | 91 | 75 | ||
| Finance Cost | 7 | 5 | 13 | 9 | ||
| PBT | 261 | 204 | 28.1% | 489 | 385 | 27.2% |
| Margins | 29.8% | 27.9% | 29.3% | 27.5% | ||
| Income Tax | 67 | 51 | 125 | 98 | ||
| PAT | 194 | 152 | 27.5% | 364 | 286 | 27.3% |
| Margins | 22.2% | 20.8% | 21.8% | 20.4% | ||
| EPS | 11.5 | 9.0 | 27.5% | 21.7 | 17.0 | 27.6% |
| FH | ||||||
Source: BSE
